Literature DB >> 22092561

Bacterial translocation in cirrhosis is not caused by an abnormal small bowel gut microbiota.

Helen Steed1, George T Macfarlane, Katie L Blackett, Sandra Macfarlane, Michael H Miller, Bahram Bahrami, John F Dillon.   

Abstract

Sepsis is common in liver cirrhosis, and animal studies have shown the gut to be the principal source of infection, through bacterial overgrowth and translocation in the small bowel. A total of 33 patients were recruited into this study, 10 without cirrhosis and 23 with cirrhotic liver disease. Six distal duodenal biopsies were obtained and snap frozen for RNA and DNA extraction, or frozen for FISH. Peripheral venous bloods were obtained from 30 patients, including 17 chronic liver disease patients. Samples were analysed by real-time PCR, to assess total bacteria, bifidobacteria, bacteroides, enterobacteria, staphylococci, streptococci, lactobacilli, enterococci, Helicobacter pylori and moraxella, as well as TNF-α, IL-8 and IL-18. There was no evidence of bacterial overgrowth with respect to any of the individual bacterial groups, with the exception of enterococci, which were present in higher numbers in cirrhotic patients (P = 0.04). There were no significant differences in any of the cytokines compared to the controls. The small intestinal mucosal microbiota in cirrhotic patients was qualitatively and quantitatively normal, and this shifts the focus of disease aetiology to factors that reduce gut integrity, failure of mechanisms to remove translocating bacteria, or the large bowel as the source of sepsis.
© 2011 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22092561     DOI: 10.1111/j.1574-695X.2011.00857.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  8 in total

Review 1.  Microbial Profiles of Cirrhosis in the Human Small Intestine.

Authors:  Tien S Dong; Jonathan P Jacobs; Shehnaz K Hussain
Journal:  Curr Gastroenterol Rep       Date:  2019-08-23

Review 2.  The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.

Authors:  Marco Sanduzzi Zamparelli; Alba Rocco; Debora Compare; Gerardo Nardone
Journal:  United European Gastroenterol J       Date:  2017-05-08       Impact factor: 4.623

3.  Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Hepatol Int       Date:  2018-10-04       Impact factor: 6.047

4.  Supplemental thymol and carvacrol increases ileum Lactobacillus population and reduces effect of necrotic enteritis caused by Clostridium perfringes in chickens.

Authors:  Dafei Yin; Encun Du; Jianmin Yuan; Jinxin Gao; YouLi Wang; Samuel E Aggrey; Yuming Guo
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

5.  Interactions between a pathogenic Blastocystis subtype and gut microbiota: in vitro and in vivo studies.

Authors:  John Anthony Yason; Yi Ran Liang; Chin Wen Png; Yongliang Zhang; Kevin Shyong Wei Tan
Journal:  Microbiome       Date:  2019-03-11       Impact factor: 14.650

6.  Bifidobacterial Transfer from Mother to Child as Examined by an Animal Model.

Authors:  Walter Mancino; Sabrina Duranti; Leonardo Mancabelli; Giulia Longhi; Rosaria Anzalone; Christian Milani; Gabriele Andrea Lugli; Luca Carnevali; Rosario Statello; Andrea Sgoifo; Douwe van Sinderen; Marco Ventura; Francesca Turroni
Journal:  Microorganisms       Date:  2019-08-27

7.  In vitro antibacterial activity of thymol and carvacrol and their effects on broiler chickens challenged with Clostridium perfringens.

Authors:  Encun Du; Liping Gan; Zhui Li; Weiwei Wang; Dan Liu; Yuming Guo
Journal:  J Anim Sci Biotechnol       Date:  2015-12-24

8.  Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology.

Authors:  Yanfei Chen; Feng Ji; Jing Guo; Ding Shi; Daiqiong Fang; Lanjuan Li
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.